New York State Teachers Retirement System Increases Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

New York State Teachers Retirement System boosted its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 23.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,474 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,350 shares during the quarter. New York State Teachers Retirement System’s holdings in Collegium Pharmaceutical were worth $384,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Altshuler Shaham Ltd purchased a new position in Collegium Pharmaceutical during the fourth quarter worth about $28,000. Captrust Financial Advisors boosted its stake in shares of Collegium Pharmaceutical by 97.5% in the first quarter. Captrust Financial Advisors now owns 2,151 shares of the specialty pharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,062 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 233.9% in the first quarter. PNC Financial Services Group Inc. now owns 2,224 shares of the specialty pharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,558 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Collegium Pharmaceutical by 264.6% in the second quarter. Tower Research Capital LLC TRC now owns 3,318 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 2,408 shares during the period. Finally, UBS Group AG boosted its stake in shares of Collegium Pharmaceutical by 300.0% in the third quarter. UBS Group AG now owns 3,556 shares of the specialty pharmaceutical company’s stock valued at $57,000 after purchasing an additional 2,667 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have recently commented on COLL. Needham & Company LLC reissued a “buy” rating and issued a $40.00 price objective on shares of Collegium Pharmaceutical in a research note on Thursday, April 11th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $37.00 target price (up previously from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Truist Financial raised their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a report on Monday, February 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $39.00 target price (up previously from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Friday, March 29th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $34.77 on Friday. The firm has a market capitalization of $1.14 billion, a P/E ratio of 29.47 and a beta of 1.03. Collegium Pharmaceutical, Inc. has a one year low of $20.83 and a one year high of $40.95. The company’s fifty day moving average is $36.82 and its two-hundred day moving average is $30.72. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.20 by $0.25. The company had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. Analysts forecast that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.